The Indian pharma market is expected to reach $65 billion by 2024 and $130 billion by 2030, growing at a steady pace of over 10%. This year-on-date growth has been driven by factors like:
- Expanding market opportunities: Rising income levels and increasing healthcare awareness are boosting demand for pharmaceuticals within India.
- Heightened demand in the USA: India supplies over 40% of generic medications in the US, and this demand is expected to continue growing.
- Critical shortages in the US and Europe: Supply chain disruptions have created opportunities for Indian pharma companies to fill the gap.
Future Potential:
The industry is well-positioned for continued growth due to:
- Strong domestic market: India’s large and growing population offers a strong base for pharma sales.
- Increased exports: Indian pharma companies are increasingly recognized for their quality and affordability, leading to higher exports.
- Focus on innovation: Companies are investing in research and development of new drugs and technologies, including biosimilars and specialty drugs.
- Government support: The Indian government is actively promoting the pharma industry through various initiatives and policies.
Challenges:
Despite the positive outlook, some challenges remain:
- Price pressure in developed markets: Competition from other generic drug producers could put downward pressure on prices.
- Regulatory hurdles: Stringent regulations in some markets can be challenging for Indian companies to navigate.
- Intellectual property concerns: Protecting intellectual property rights is crucial for attracting investment and encouraging innovation.
